CTLA4 and cancer: Among these therapies, immune checkpoint inhibitors (ICIs) are a form of targeted therapy that disrupt the immune evasion mechanisms of cancer cells by inhibiting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1).